$3.815
-0.176 (-4.62%)At close
BOLT News
BOLT Events
BDC-4182 Reports Q2 Revenue of $5,000
Reports Q2 revenue $5,000, consensus $500,000. "In the second quarter, we continued to make meaningful progress in the ongoing BDC-4182 Phase 1/2 study in patients with gastric and gastroesophageal cancer. We are currently treating patients in Cohort 4. To date, BDC-4182 has been well tolerated, and we are seeing activity consistent with our immune-stimulating mechanism," said Willie Quinn, President and Chief Executive Officer. "We expect to report initial clinical data from BDC-4182 with our third quarter 2026 results."
BDC-4182 Reports Q4 Revenue of $2.5M, Exceeding Expectations
Reports Q4 revenue $2.5M, consensus $857,250. "BDC-4182 is the first of our next-generation Boltbody ISACs to enter the clinic, and we saw a clear difference versus our first-gen ISACs in terms of immune response from the very first patient treated," said Willie Quinn, president and CEO. "The ISAC mechanism is radically different from ADCs and T cell engagers, and we believe that demonstrating anti-tumor activity with BDC-4182 will unlock an entirely new approach to treating cancer. We continue to enroll patients with gastric and gastroesophageal cancers in the Phase 1 dose-escalation trial and remain on track to report initial data in the third quarter of 2026."
Bolt Biotherapeutics announces Q3 EPS of $3.72, below consensus estimate of $5.39
Reports Q3 revenue $2.17M, consensus $820,800. "In the third quarter, we focused on developing BDC-4182, the first next-generation Boltbody ISAC in our pipeline. We are actively enrolling patients with gastric and gastroesophageal cancer in the Phase 1 dose-escalation study. We now look forward to presenting initial data in the third quarter of 2026," said Willie Quinn, President and Chief Executive Officer. "With our cash runway now expected to extend into 2027, we are in a financial position to create long-term value for our shareholders and fulfill our mission of bringing new treatment options to patients with cancer."
Bolt Biotherapeutics to Cut Workforce by Half and Provide Update on BDC-4182 Study
Bolt Biotherapeutics announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a Boltbody ISAC clinical candidate targeting claudin 18.2, a clinically validated target in oncology. A strong immune response was observed at the initial dose levels and the company is in the process of modifying the clinical trial protocol to allow for step-up dosing, which has been successfully used commercially for T-cell engagers. BDC-4182 preclinical data supports this approach. As a result of the update to the clinical trial protocol for BDC-4182, Bolt now expects to report initial clinical data in the third quarter of 2026. To conserve capital and maintain long-term shareholder value, the company is implementing a workforce reduction of approximately 50%, extending its cash runway into 2027.
Bolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)
Reports Q2 revenue $1.8M, consensus $819,750. "In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody(TM) ISAC in our pipeline," said Willie Quinn, president and CEO. "We are now conducting a Phase 1 dose-escalation study for patients with gastric and gastroesophageal cancer in Australia, and will expand to other countries in the second half of 2025. We look forward to presenting initial data in the first half of 2026. We also continue to seek a partner for further development of our dectin-2 agonist antibody BDC-3042, which demonstrated activity in lung cancer patients in the form of a partial response (PR) at the highest dose tested. Patients at the highest doses also had a strong immune response consistent with our expectations based on preclinical data."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.